CN101904859B - Rhoifolin and hyperin composition and application of medicines prepared therefrom - Google Patents
Rhoifolin and hyperin composition and application of medicines prepared therefrom Download PDFInfo
- Publication number
- CN101904859B CN101904859B CN2010102537728A CN201010253772A CN101904859B CN 101904859 B CN101904859 B CN 101904859B CN 2010102537728 A CN2010102537728 A CN 2010102537728A CN 201010253772 A CN201010253772 A CN 201010253772A CN 101904859 B CN101904859 B CN 101904859B
- Authority
- CN
- China
- Prior art keywords
- hyperin
- radix seu
- seu folium
- tosicodendri delavayi
- folium tosicodendri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a rhoifolin and hyperin composition which is a composition prepared from 20%-80% of rhoifolin and 80%-20% of hyperin in percentage by weight. The composition can be used as a neuraminidase inhibitor for preventing and treating flu and can be made into pharmaceutically acceptable formulations.
Description
Technical field
The present invention relates to a kind of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions and preparation medicinal usage thereof.
Background technology
Influenza virus is serious day by day at present; And influenza virus and respiratory tract disease and the systemic disease that causes are closely related; China is one of influenza country occurred frequently, and is not only populous, and living habit also helps the relay of influenza virus; The number of times of falling ill for each person every year reaches 0.3～0.7 time not to be waited, and key population reaches 2～4 times.There is serious threat in influenza to the mankind, New Development kind influenza virus especially, and it not only causes other infected by microbes of Secondary cases, and can directly cause organ to destroy and the allergy causing death.But the method and the treatment means that do not have efficacious therapy influenza virus and disease (influenza) thereof at present as carry out the inflammatory reaction treatment to clinical symptoms, are cured the symptoms, not the disease.The method of present modal prevention and treatment influenza virus is to use influenza virus vaccine inoculation, non-specific anti virus herb or Western medicine oseltamivir phosphate (oseltamivir phosphate capsule)-neuraminidase inhibitor.Yet influenza virus vaccine prophylactic immunization drawback is that the inoculation crowd is selective, is not that everybody can inoculate.In addition, the influenza virus vaccine protective rate is not high, and guard time is also lacked (3～6 months).Though most of non-specific anti virus herbs lay claim to antivirus action at present, be not to influenza virus, and antivirus action mechanism are unclear.At many kind treatment affection of exogenous wind-cold of our former studies, the Chinese prescription of the flu that doctor trained in Western medicine is thought does not have the effect of direct resisiting influenza virus.Briefly, the Chinese prescription of not every treatment flu all has the effect of clear and definite inhibition influenza virus.Western medicine " oseltamivir phosphate (oseltamivir phosphate capsule; (3R; 4R, 5S)-amino-3 (1-third the 2-ethoxyethyl acetate)-1-cyclohexene-1 carboxylic acid, ethyl ester phosphate of 4-acetamide-5-) " be neuraminidase inhibitor, influenza virus is got into cell has specific inhibitory effect; But not only cost an arm and a leg, and have that some patients take that the back vomiting occurs, feels sick, side reactions such as insomnia, headache, stomachache, diarrhoea, dizziness, fatigue, nasal obstruction, pharyngalgia and cough.Oseltamivir phosphate capsule is that the esterase that is positioned at liver and intestinal in vivo is converted into active metabolite and plays the neuraminidase effect that suppresses, and also will influence its drug effect if patient's liver and intestinal organ dysfunction are undesired.In addition, the renal insufficiency patient also wants careful usefulness.
Traditional Chinese medicine thinks that leaf of Turpinia pomifera (Roxb) D O. has heat-clearing and toxic substances removing, relieving sore throat and diminishing swelling, promoting blood circulation and stopping pain.Be used for the tonsillitis sore throat, laryngopharynx swelling and pain, sore swollen toxin falls and pounces on the pain of injury; Radix seu Folium Tosicodendri Delavayi glucoside, hyperin are one of main component of leaf of Turpinia pomifera (Roxb) D O..Exocarpium Citri Grandis has cold expelling, dampness, promoting the circulation of QI, expectorant.Be used for the cough due to wind and cold, the itching of the throat abundant expectoration, food stagnation is got sick from drinking too much wine, and the vomiting and nausea painful abdominal mass is vexed; Radix seu Folium Tosicodendri Delavayi glucoside is one of Exocarpium Citri Grandis main component.Herba Hyperici Monogyni has soothing liver-QI for relieving depression, clearing away heat-damp and promoting diuresis, reducing swelling and alleviating pain.It is not smooth to be used for feelings will, and the stagnation of QI is gloomy, arthralgia, dysuria.Hyperin is one of main component of Herba Hyperici Monogyni, and hyperin is to myocardial ischemia-reperfusion, and cerebral ischemia re-pouring, cerebral infarction all show good protective action, also have analgesia, antioxidation, protection cardiac muscle, liver effect.But do not find that leaf of Turpinia pomifera (Roxb) D O. and contained Radix seu Folium Tosicodendri Delavayi glucoside and hyperin, Exocarpium Citri Grandis and contained Radix seu Folium Tosicodendri Delavayi glucoside, Herba Hyperici Monogyni and contained hyperin thereof thereof thereof have the effect that suppresses influenza infection, duplicates, and do not find to have the effect that suppresses neuraminidase yet.
Summary of the invention
The purpose of this invention is to provide Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions; It can suppress influenza neuraminidase hydrolysis cell surface sialic acid; Cause influenza virus not combine with cell surface receptor and to get in the cell; And reduce influenza virus in intracellular generation, and duplicate thereby suppress influenza virus effectively pointedly, more importantly be that the present invention provides a kind of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions can overcome the side reaction drawback of existing medicine.
Radix seu Folium Tosicodendri Delavayi glucoside provided by the invention, hyperin compositions, the molecular formula of wherein said Radix seu Folium Tosicodendri Delavayi glucoside: C
27H
30O
14, molecular weight: 578.52, the structural formula of said Radix seu Folium Tosicodendri Delavayi glucoside is following:
The molecular formula of said hyperin: C
21H
20O
12, molecular weight: 464.38, the structural formula of said hyperin is following:
Wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 80%～20%, hyperin 20%～80%.
Preferably, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 75%～25%, hyperin 25%～75%.
Preferably, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 60%～40%, hyperin 40%～60%.
Preferably, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 55%～45%, hyperin 45%～55%.
Preferably, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 50%, hyperin 50%.
On the other hand; The present invention also provides the method for distilling of described Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions; Wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin are extracted acquisition from leaf of Turpinia pomifera (Roxb) D O., said method for distilling is following: get leaf of Turpinia pomifera (Roxb) D O., add 30%～90% alcohol reflux 1～3 time of 5～15 times of amounts; Each reflux, extract, 1～3 hour filters; Merging filtrate reclaims ethanol, and aqueous solution is collected the eluting part through the macroporous resin column eluting; Concentrating under reduced pressure, drying, the mixing total glycosides of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin, through separating; Merge Radix seu Folium Tosicodendri Delavayi glucoside, hyperin stream part respectively, crystallization obtains Radix seu Folium Tosicodendri Delavayi glucoside, the pure article of hyperin.
Preferably, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin adopt following method for distilling to obtain: get leaf of Turpinia pomifera (Roxb) D O., add 12 times of amount 70% alcohol reflux 1.5 hours; Filter, filtering residue adds 10 times of amount 70% alcohol reflux 1.5 hours again, filters; Merge extracted twice liquid, reclaim ethanol, aqueous solution is through the macroporous resin column eluting; Collect the eluting part, concentrating under reduced pressure, drying.
Preferably, wherein the D101 macroporous resin column of aqueous solution through having handled well distinguished water, 5%～10% ethanol, 30%～55% ethanol, 1% sodium hydroxide solution eluting, collects 30%～55% ethanol elution part, concentrating under reduced pressure, drying.
Preferably, wherein mix total glycosides through silica gel column chromatography, Sephadex LH-20 column chromatography for separation, merge Radix seu Folium Tosicodendri Delavayi glucoside, hyperin stream part respectively, crystallization obtains the pure article of Radix seu Folium Tosicodendri Delavayi glucoside and hyperin.
The purposes that the present invention also provides Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions to be used to prepare prevention and to treat the medicine of influenza and complication disease thereof.
Preferably, Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are used to suppress influenza virus.
Preferably, Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are used to suppress influenza virus FM1.
Preferably, Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are used to suppress neuraminidase.
Preferably, its complication is meant renal failure.
Preferably, its complication is meant splenic trauma or/and injury of lung.
Radix seu Folium Tosicodendri Delavayi glucoside of the present invention, hyperin can be from the various medical materials that contain Radix seu Folium Tosicodendri Delavayi glucoside, hyperin, to obtain Radix seu Folium Tosicodendri Delavayi glucoside, hyperin bullion or Radix seu Folium Tosicodendri Delavayi glucoside, hyperin monomeric compound as extracting in leaf of Turpinia pomifera (Roxb) D O., Exocarpium Citri Grandis, the Herba Hyperici Monogyni leaf.
At last, the present invention also provides a kind of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin composite preparation, and said preparation is a main active with the above-mentioned Radix seu Folium Tosicodendri Delavayi glucoside of the present invention, hyperin compositions.
Experimental data proves; Radix seu Folium Tosicodendri Delavayi glucoside of the present invention, hyperin compositions are effectively to suppress the neuraminic acid enzyme component, and Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are along with the using dosage size variation, and it suppresses the active ability of neuraminidase; Be also corresponding the changing of height of neuraminic acid enzyme inhibition rate; And one-tenth positive correlation, Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions can be through suppressing influenza virus surface neuraminidase, and then suppress that influenza virus gets into the cell the inside, the influenza virus that suppresses to have got into the cell the inside duplicates, breeds; Thereby infection, the growth of influenza virus pair cell have been reduced; And prevention and treatment influenza and complication thereof, can also suppress influenza neuraminidase hydrolysis cell surface sialic acid, cause influenza virus not combine with cell surface receptor and to get in the cell; And reduce influenza virus in intracellular generation, more importantly be that the present invention provides a kind of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions can overcome the side reaction drawback of existing medicine.
And medical science and study of pharmacy personnel can't not do the inhibition influenza infection, duplicate in advance; Or under the prerequisite of the experiment of inhibition neuraminidase, learn that in advance Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions have prevention and treat the good result that the influenza virus sexuality is emitted.
In sum, Radix seu Folium Tosicodendri Delavayi glucoside provided by the invention, hyperin composition and use thereof bring significant technique effect.
The specific embodiment
Embodiment 1
Radix seu Folium Tosicodendri Delavayi glucoside of the present invention, hyperin compositions, the molecular formula of wherein said Radix seu Folium Tosicodendri Delavayi glucoside: C
27H
30O
14, molecular weight: 578.52, the structural formula of said Radix seu Folium Tosicodendri Delavayi glucoside is following:
The molecular formula of said hyperin: C
21H
20O
12, molecular weight: 464.38, the structural formula of said hyperin is following:
Get Folium Isatidis 1000g, add 12 times of amount 70% alcohol reflux 2 hours, filter, filtering residue adds 10 times of amount 70% alcohol reflux 1.5 hours again; Filter, merge extracted twice liquid, reclaim ethanol, the D101 macroporous resin column of aqueous solution through having handled well; Water, 10% ethanol, 45% ethanol, 1% sodium hydroxide solution eluting are collected 45% ethanol elution part, concentrating under reduced pressure respectively; Drying, the mixing total glycosides of 30 above Radix seu Folium Tosicodendri Delavayi glucosides, hyperin, through silica gel column chromatography, Sephadex LH-20 column chromatography for separation; Merge Radix seu Folium Tosicodendri Delavayi glucoside, hyperin stream part respectively, crystallization obtains Radix seu Folium Tosicodendri Delavayi glucoside (3.5g; Purity: 98.5%) and Radix seu Folium Tosicodendri Delavayi glucoside (1.5g, purity: pure article 98.5%), through respectively with the UV of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin standard substance, IR, ESI-MS,
1H-NMR,
13C-NMR has relatively confirmed the structure of above-mentioned two chemical compounds.
In addition, nuezhenoside provided by the invention, hyperin also can be extracted acquisition respectively, like following listed examples.
Embodiment 2
Get Exocarpium Citri Grandis 100000g, add 12 times of amount 70% alcohol reflux 2 hours, filter, filtering residue adds 10 times of amount 70% alcohol reflux 1.5 hours again; Filter, merge extracted twice liquid, reclaim ethanol; The D101 macroporous resin column of aqueous solution through having handled well, water, 10% ethanol, 45% ethanol, 1% sodium hydroxide solution eluting are collected 45% ethanol elution part respectively; Concentrating under reduced pressure, drying, the mixing total glycosides of 30% above Radix seu Folium Tosicodendri Delavayi glucoside; Through silica gel column chromatography, Sephadex LH-20 column chromatography for separation, merge Radix seu Folium Tosicodendri Delavayi glucoside stream part, crystallization; Obtain Radix seu Folium Tosicodendri Delavayi glucoside (450g, purity: pure article 98.9%), through respectively with the UV of Radix seu Folium Tosicodendri Delavayi glucoside standard substance, IR, ESI-MS,
1H-NMR,
13C-NMR has relatively confirmed the structure of Radix seu Folium Tosicodendri Delavayi glucoside.
Embodiment 3
Get Exocarpium Citri Grandis 100000g, add 10 times of amount 60% alcohol reflux 2 hours, filter, filtering residue adds 8 times of amount 60% alcohol reflux 1.5 hours again; Filter, merge extracted twice liquid, reclaim ethanol; The D101 macroporous resin column of aqueous solution through having handled well, water, 10% ethanol, 45% ethanol, 1% sodium hydroxide solution eluting are collected 45% ethanol elution part respectively; Concentrating under reduced pressure, drying, the mixing total glycosides of 30% above Radix seu Folium Tosicodendri Delavayi glucoside; Through silica gel column chromatography, Sephadex LH-20 column chromatography for separation, merge Radix seu Folium Tosicodendri Delavayi glucoside stream part, crystallization; Obtain Radix seu Folium Tosicodendri Delavayi glucoside (455g, purity: pure article 98.6%), through respectively with the UV of Radix seu Folium Tosicodendri Delavayi glucoside standard substance, IR, ESI-MS,
1H-NMR,
13C-NMR has relatively confirmed the structure of Radix seu Folium Tosicodendri Delavayi glucoside.
Embodiment 4
Get Herba Hyperici Monogyni 10000g, add 12 times of amount 70% alcohol reflux 1.5 hours, filter, filtering residue adds 10 times of amount 70% alcohol reflux 1.5 hours again; Filter, merge extracted twice liquid, reclaim ethanol; The D101 macroporous resin column of aqueous solution through having handled well, water, 10% ethanol, 45% ethanol, 1% sodium hydroxide solution eluting are collected 45% ethanol elution part respectively; Concentrating under reduced pressure, drying, the mixing total glycosides of 30% above hyperin; Through silica gel column chromatography, Sephadex LH-20 column chromatography for separation, merge hyperin stream part, crystallization; Obtain hyperin (85g, purity: pure article 98.6%), through respectively with the UV of hyperin standard substance, IR, ESI-MS,
1H-NMR,
13C-NMR has relatively confirmed the structure of hyperin.
Embodiment 5
With Radix seu Folium Tosicodendri Delavayi glucoside (14g) and the mixed of hyperin (6g), get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions behind stirring, grinding, the mix homogeneously with 7: 3.
Embodiment 6
With Radix seu Folium Tosicodendri Delavayi glucoside (12g) and the mixed of hyperin (8g), get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions behind stirring, grinding, the mix homogeneously with 6: 4.
Embodiment 7
With Radix seu Folium Tosicodendri Delavayi glucoside (10g) and the mixed of hyperin (10g), get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions behind stirring, grinding, the mix homogeneously with 5: 5.
Embodiment 8
With Radix seu Folium Tosicodendri Delavayi glucoside (6g) and the mixed of hyperin (14g), get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions behind stirring, grinding, the mix homogeneously with 3: 7.
Embodiment 9
With Radix seu Folium Tosicodendri Delavayi glucoside (8g) and the mixed of hyperin (12g), get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions behind stirring, grinding, the mix homogeneously with 2: 3.
Provide some preferred embodiments of Radix seu Folium Tosicodendri Delavayi glucoside of the present invention and hyperin mass percent below in conjunction with table 1; But the two the content of composition of the present invention is not limited to listed numerical value in this table; For a person skilled in the art, fully can be in table rationally summarize and reasoning on the basis of listed numerical range.
Table 1: Radix seu Folium Tosicodendri Delavayi glucoside, hyperin account for the percentage by weight (%) of compositions
Experimental data 1: Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the active inhibitory action of neuraminidase
Get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions that embodiment 6 method for preparinies are obtained, add suitable quantity of water and make dissolving, application neuraminidase inhibitor identification kit is measured Radix seu Folium Tosicodendri Delavayi glucoside, the hyperin compositions suppresses tiring of neuraminidase (N1) and sees table 2.
(1). standard curve is prepared: a. every hole in 96 hole luciferase targets adds 70 μ l neuraminidases and detects buffer; B. every hole adds 0,1,2,5,7.5,10 μ l H5N1 neuraminidases more respectively; C. every hole adds 0～20 μ l Milli-Q water again.
(2). the preparation of sample detection: a. every hole in 96 hole luciferase targets adds 70 μ l neuraminidases and detects buffer; B. every hole adds 10 μ l H5N1 neuraminidases again; C. every hole adds 0～10 μ l Radix seu Folium Tosicodendri Delavayi glucoside, hyperin composition sample again; D. every hole adds 0～10 μ l Milli-Q water again.
(3). detect step:
A. vibrate the about 1min of mixing;
B.37 ℃ hatch 2min inhibitor and H5N1 neuraminidase are fully interacted, the sample of doing standard curve is also hatched together;
C. every hole adds 10 μ l neuraminidase fluorogenic substrates;
D. vibrate the about 1min of mixing again;
E.37 carry out fluoremetry after ℃ hatching 20～30min.Excitation wavelength is 360nm, and emission wavelength is 440nm.
(4). calculate the inhibition percentage ratio of sample according to standard curve, and do and calculate Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions IC50 behind the concentration curve for the H5N1 neuraminidase for the H5N1 neuraminidase.The suppression ratio IC50 that Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions reach neuraminidase is 0.045g/L.See table 2.
Table 2. Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions suppress the activity of neuraminidase
Can be clear that according to above-mentioned experimental result:
(1). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions can extract effective inhibition neuraminic acid enzyme component;
(2). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are along with the using dosage size variation, and it suppresses the active ability of neuraminidase, and promptly the height of neuraminic acid enzyme inhibition rate is also corresponding changes, and become positive correlation;
(3). visible by above-mentioned experiment; Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions can be through suppressing influenza virus surface neuraminidase; And then suppress that influenza virus gets into the cell the inside, the influenza virus that suppresses to have got into the cell the inside duplicates, breeds; Thereby reduced infection, the growth of influenza virus pair cell, and prevention and treatment influenza and complication thereof.
Medical science and study of pharmacy personnel can't not do the inhibition influenza infection, duplicate in advance, or under the prerequisite of the experiment of inhibition neuraminidase, learn that in advance Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions have prevention and treat the good result that the influenza virus sexuality is emitted.
Experimental data 2: Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions infect the inhibitory action of Embryo Gallus domesticus to influenza virus
Get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions that embodiment 6 method for preparinies are obtained, use influenza virus A-prime Mus lung adapted strain (FM1) and (H1N1) identify that Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions suppress the ability that the FM1 influenza virus is duplicated and suppresses in Embryo Gallus domesticus.(1). FM1 influenza virus liquid is inoculated in 10d no-special pathogen in age chick embryo allantois intracavity, and every embryo 0.2ml is hatched 72h for 37 ℃, observes and calculate half Embryo Gallus domesticus infective dose (EID50).(2). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions adopt the toxic action of Embryo Gallus domesticus; Physiological saline solution is done to be inoculated in 10d no-special pathogen in age chick embryo allantois intracavity behind the serial dilution to Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions; Every embryo 0.2ml, each concentration is inoculated 6 embryos, hatches for 37 ℃; Observe Embryo Gallus domesticus growth promoter situation, can survive the Cmax of 96h as the TD of medicine with Embryo Gallus domesticus.(3). Radix seu Folium Tosicodendri Delavayi glucoside, the hyperin compositions inhibitory action to influenza virus in Embryo Gallus domesticus adopts; 0.1ml influenza virus liquid and different dilution Radix seu Folium Tosicodendri Delavayi glucosides, hyperin compositions mix; 37 ℃ of effect 2h; Be inoculated in 10d no-special pathogen in age chick embryo allantoic cavity, every winding kind 6 embryos are hatched 72h for 37 ℃.The virus attack amount is 50EID50, establishes virus control, physiological saline solution normal control simultaneously, calculates Radix seu Folium Tosicodendri Delavayi glucoside, the hyperin compositions median effective dose (ED50) to viral inhibition.
(1) the .FM1 influenza virus is calculated through the Reed-Muench method the virulence of Embryo Gallus domesticus, and its EID50 is 10
-5.07(2). after Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are inoculated in Embryo Gallus domesticus, its growth promoter and normal control group basically identical.The 96h Embryo Gallus domesticus is all survived.Embryo Gallus domesticus gives Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions stock solution is not seen chicken embryo death, so can think that TD0 is 1.9g/L.(3). Radix seu Folium Tosicodendri Delavayi glucoside, the hyperin compositions inhibitory action to influenza virus in Embryo Gallus domesticus is seen table 3.
Table 3. Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions infect the inhibitory action of Embryo Gallus domesticus to influenza virus
Compare with the virus control group:
*P＜0.05
Can know that by table 3 Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions have significant inhibitory effect (P＜0.05), ED at 0.059～0.475g/L to influenza virus
50Be 0.059 ± 0.0029g/L, TI is 81.36 ± 4.27.
Experimental data 3: Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions influence the FM1 influenza virus
Get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions that embodiment 6 method for preparinies are obtained, use influenza virus A-prime Mus lung adapted strain (FM1) and (H1N1) identify that Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions suppress the ability of FM1 influenza virus virulence.(1) .FM1 adopts cell ID 50, median infective dose (TCID50) micromethod to the toxicity test of Testis et Pentis Canis passage cell (MDCK).(2). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions adopt the DMEM of serum-free that Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are done to be inoculated in the mdck cell hole that forms monolayer behind the serial dilution to the toxicity test of mdck cell; Every hole 100 μ l; Each dilution factor repeats 4 holes, establishes the normal cell contrast simultaneously.Culture plate is put 37 ℃, 5%CO
2Cultivate in the incubator, observation of cell pathological changes every day (CPE) is observed 3d continuously, with " +～++ ++ " the record result, press the Reed-Muench method and calculate medicine median toxic concentration (TD50) and maximal non-toxic concentration (TD0).(3). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions suppress the effect of FM1 influenza virus and measure: mdck cell 5 * 10
5/ ml, every hole 100 μ l, in 96 orifice plates, 37 ℃, the interior cultivation of 5%CO2 incubator are inhaled and remove culture fluid in the hole next day, add 100TCID50 influenza virus liquid, every hole 100 μ l, supernatant is removed in suction behind 37 ℃ of absorption 1h.Wash 2 times with phosphate buffer (PBS); TD0 with medicine is the 1st hole, and the DMEM liquid of reuse serum-free is made serial dilution to Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions, adds respectively in the cell of above-mentioned infective virus; Establish virus control and normal control group simultaneously, 37 ℃, 5%CO
2Cultivate in the incubator, observe the mdck cell characteristics of lesion that influenza virus produces every day, i.e. cell monolayer degeneration becomes circle etc., and 3d calculates 50% of medicine and suppresses pathological changes concentration (IC50) and therapeutic index (TI) continuously.The calculating of TI: TI=TD50/IC50, the TI value is big more, shows that the safety range of medicine is big more.With Kruskal-Walis and Mann-Whitney method of inspection comparative test group and the cytopathic difference of virus control group; Drug dose and suppression ratio that virus infected cell is avoided cytopathy (CPE) takes place are carried out correlation analysis, judge whether amount validity response relation.
(1) the .FM1 influenza virus is calculated through the Reed-Muench method the virulence of mdck cell, and its TCID50 is 10
-4.81(2). the TD0 of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions mdck cell is respectively 0.77g ± 0.042g/L.(3). after Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions made serial dilution, the 100TCID50 influenza virus is carried out inhibition test, median effective dose IC50 and the TI value of calculating medicine are big or small, and the result sees table 4.
Table 4. Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the IC of FM1 influenza virus
50(mg/100ml) and TI (x ± s)
Can be known that by table 4 IC50 of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions is low, TI is high.Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions suppress the cytopathogenic effect of FM1 influenza virus and all strengthen along with the increase of drug dose.Drug dose and medicine are shown that to the correlation analysis that the suppression ratio of CPE carries out the dosage of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions and medicine are to being tangible positive correlation between the CPE suppression ratio.
Experimental data 4: Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the spleen index and the exponential influence of lung of influenza virus infection FM1 strain in the mice body
Get Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions that embodiment 6 method for preparinies are obtained, use influenza virus A-prime Mus lung adapted strain (FM1) and (H1N1) identify the dead protective effect of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions influenza virus infection FM1 strain in the mice body.(1). influenza virus FM1 strain virus is inoculated every group of 10 BALB/C mices respectively, male and female half and half after doing 10 times of doubling dilutions.After the slight anesthesia of ether, give and different dilution viruses respectively for every group, every mice collunarium is inoculated 20 μ l.Observe the dead mouse situation of 10d, calculating LD50 by the Reed-Muench method is 10
-1.36So confirm that the used modeling concentration of experiment is 10LD50.(2). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the dead protective effect of influenza virus infection FM1 strain in the mice body: normal control group, influenza virus FM1 strain virus matched group, Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions 0.11875g/L, 0.2375g/L, 0.475g/L, 0.95g/L dose groups etc. are irritated stomach respectively, irritate gastric capacity and only are 0.4ml/.Behind the 3d, each is organized under the slight anesthesia of ether with 10LD50 influenza virus FM1 strain collunarium infecting mouse 20 μ l/ except that the normal control group.The normal control group gives the normal saline with volume simultaneously.4 groups of administration are continued administration, normal control group and influenza virus FM1 strain virus control group administered physiological saline 8 days, and dosage is the same.Day by day observe animal morbidity and record death toll, observed altogether 14 days, calculate mortality rate (mortality rate=every group of death toll/every group of total mice * 100%), the result sees table 5.(3). Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the exponential influence of influenza virus infection FM1 strain lung in the mice body: normal control group, influenza virus FM1 strain virus matched group, Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions 0.11875g/L, 0.2375g/L, 0.475g/L, 0.95g/L dose groups etc. are irritated stomach respectively, irritate gastric capacity and only are 0.4ml/.After 3 days, each is organized under the slight anesthesia of ether with 1.0LD50 influenza virus FM1 strain collunarium infecting mouse 20 μ l/ except that the normal control group.The normal control group gives the normal saline with volume simultaneously.4 groups of administration are continued administration, normal control group and influenza virus FM1 strain virus control group administered physiological saline 8 days, and dosage is the same.Behind viral infection, put to death mice on the 8th day, weigh, get lung and claim that lung is heavy, calculates lung index (lung index=lung quality/body constitution amount * 100%); In addition, get spleen and claim that spleen is heavy, calculate spleen index (spleen index=spleen quality/body constitution amount * 100%), the result sees table 6.
Table 5. Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are protected the result to the death of influenza virus infection FM1 strain in the mice body
Annotate: ※ ※ P＜0.01VS influenza virus model group ※ P＜0.05VS influenza virus model group
Table 6. Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the spleen index and the exponential influence of lung of influenza virus infection FM1 strain in the mice body
Annotate: #P＜0.05VS normal control group is annotated: ※ ※ p＜0.001 VS influenza virus model group ※ p＜0.05VS influenza virus model group
(1). can know that by table 5 Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions have significant protective effect (p＜0.01-p＜0.05) at 0.2375～0.95g/L to the influenza virus infecting mouse.
(2). can know that by table 6 Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions have significant effect (p＜0.01) at 0.475～0.95g/L to the lung index suppression ratio of influenza virus infecting mouse.
Experimental data 5: Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the influence of renal dysfunction
1) SD rat, 200～240g, Shanghai west pul-Bi Kai laboratory animal responsibility company limited, the animal quality certification number: SCXK (Shanghai) 2003-0002
2) reagent and medicine adenine, adenine, (content＞98% is the import packing, Chinese Shanghai, lot number 20010520), Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions that embodiment 3 method for preparinies are obtained;
3) test method: male SD rat, about body weight 220g, earlier feed 10 days normal growths with normal diet after, be divided into normal control group, administration experimental group and modeling matched group at random by body weight, 13～15 every group.Administration experimental group and modeling matched group are irritated stomach with adenine and are made chronic renal failure (CRF) model, irritate stomach with adenine 320mg/ (kgd), only process the about 2ml/ of suspension with distilled water, totally 20 days; Administration after 20 days; The administration experimental group is irritated stomach with Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions 2.0g/ (kgd), and Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed suspension solution (0.25g/ml) with distilled water, and about at every turn 2ml/ only; Stomach is irritated in gradation; Normal control group and modeling matched group are irritated stomach with equal-volume water, and administration was used etherization with rat after 35 days, and each item index is observed in the blood sampling of Mus arteria caudalis.
4) result:
Table 7. Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the influence of CRF kidney of rats function
Annotate: through the T check, administration Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions and modeling matched group and normal control group be " * " expression P＜0.05 relatively, and " * * " representes P＜0.01
This experiment is looked sidelong at purine with gland and is irritated after stomach sets up rat CRF model, modeling control rats lethargy, and body weight obviously reduces; Serum Bun, Ser obviously raise, and Hb obviously descends, and Ret obviously raises; Show the rat impaired renal function; Rat and normal control group difference are not remarkable after giving Radix seu Folium Tosicodendri Delavayi glucoside, hyperin combination treatment, and with the model group comparing difference very significantly, so Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are to the kidney free of toxic effects.
Claims (16)
1. a Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions, the molecular formula of wherein said Radix seu Folium Tosicodendri Delavayi glucoside: C
27H
30O
14, molecular weight: 578.52, the structural formula of said Radix seu Folium Tosicodendri Delavayi glucoside is following:
The molecular formula of said hyperin: C
21H
20O
12, molecular weight: 464.38, the structural formula of said hyperin is following:
Wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 80%～20%, hyperin 20%～80%.
2. Radix seu Folium Tosicodendri Delavayi glucoside according to claim 1, hyperin compositions, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 75%～25%, hyperin 25%～75%.
3. Radix seu Folium Tosicodendri Delavayi glucoside according to claim 2, hyperin compositions, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 60%～40%, hyperin 40%～60%.
4. Radix seu Folium Tosicodendri Delavayi glucoside according to claim 3, hyperin compositions, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 55%～45%, hyperin 45%～55%.
5. Radix seu Folium Tosicodendri Delavayi glucoside according to claim 4, hyperin compositions, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin compositions are processed by following weight proportion: Radix seu Folium Tosicodendri Delavayi glucoside 50%, hyperin 50%.
6. claim 1,2,3,4 or 5 described compositionss are used to prepare the purposes of preventing and treating the medicine of influenza and complication disease thereof.
7. purposes as claimed in claim 6 is characterized in that described compositions is used to suppress influenza virus.
8. purposes as claimed in claim 7 is characterized in that described compositions is used to suppress influenza virus FM1.
9. purposes as claimed in claim 6 is characterized in that described compositions is used to suppress neuraminidase.
10. purposes as claimed in claim 6, its complication is meant renal failure.
11. purposes as claimed in claim 6, its complication is meant splenic trauma or/and injury of lung.
12. a Radix seu Folium Tosicodendri Delavayi glucoside, hyperin composite preparation, wherein said preparation is a main active with each described Radix seu Folium Tosicodendri Delavayi glucoside of claim 1～5, hyperin compositions.
13. the method for distilling of claim 1,2,3,4 or 5 described Radix seu Folium Tosicodendri Delavayi glucosides, hyperin compositions; Wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin are extracted acquisition from leaf of Turpinia pomifera (Roxb) D O.; Said method for distilling is following: get leaf of Turpinia pomifera (Roxb) D O.; 30%～90% alcohol reflux 1～3 time that adds 5～15 times of amounts, each reflux, extract, 1～3 hour filters; Merging filtrate reclaims ethanol, and aqueous solution is collected the eluting part through the macroporous resin column eluting; Concentrating under reduced pressure, drying, the mixing total glycosides of Radix seu Folium Tosicodendri Delavayi glucoside, hyperin, through separating; Merge Radix seu Folium Tosicodendri Delavayi glucoside, hyperin stream part respectively, crystallization obtains Radix seu Folium Tosicodendri Delavayi glucoside, the pure article of hyperin.
14. method as claimed in claim 13, wherein said Radix seu Folium Tosicodendri Delavayi glucoside, hyperin adopt following method for distilling to obtain: get leaf of Turpinia pomifera (Roxb) D O., add 12 times of amount 70% alcohol reflux 1.5 hours; Filter, filtering residue adds 10 times of amount 70% alcohol reflux 1.5 hours again, filters; Merge extracted twice liquid, reclaim ethanol, aqueous solution is through the macroporous resin column eluting; Collect the eluting part, concentrating under reduced pressure, drying.
15. like claim 13 or 14 described methods; Wherein the macroporous resin column of aqueous solution through having handled well distinguished water, 5%～10% ethanol, 30%～55% ethanol, 1% sodium hydroxide solution eluting, collects 30%～55% ethanol elution part; Concentrating under reduced pressure, drying.
16., wherein mix total glycosides through silica gel column chromatography, Sephadex LH-20 column chromatography for separation like claim 13 or 14 described methods, merge Radix seu Folium Tosicodendri Delavayi glucoside, hyperin stream part respectively, crystallization obtains the pure article of Radix seu Folium Tosicodendri Delavayi glucoside and hyperin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102537728A CN101904859B (en) | 2010-08-16 | 2010-08-16 | Rhoifolin and hyperin composition and application of medicines prepared therefrom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102537728A CN101904859B (en) | 2010-08-16 | 2010-08-16 | Rhoifolin and hyperin composition and application of medicines prepared therefrom |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101904859A CN101904859A (en) | 2010-12-08 |
| CN101904859B true CN101904859B (en) | 2012-03-14 |
Family
ID=43260547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102537728A Active CN101904859B (en) | 2010-08-16 | 2010-08-16 | Rhoifolin and hyperin composition and application of medicines prepared therefrom |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101904859B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648246A (en) * | 2017-09-01 | 2018-02-02 | 江西山香药业有限公司 | The application of Rhoifolin, Hyperoside composition in treatment and/or prevention of neurodegenerative diseases medicine is prepared |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249118A (en) * | 2007-02-25 | 2008-08-27 | 胡军 | Chinese medicine extract and medicine use thereof |
-
2010
- 2010-08-16 CN CN2010102537728A patent/CN101904859B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249118A (en) * | 2007-02-25 | 2008-08-27 | 胡军 | Chinese medicine extract and medicine use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101904859A (en) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890038B (en) | Nuezhenoside-rhoifolin-hyperin composite and application in medicinal preparation thereof | |
| CN101906122B (en) | Method for extracting rhoifolin and prepared medicament application thereof | |
| CN101891785B (en) | Extraction method of hyperin and application thereof in medicament preparation | |
| CN101129455B (en) | Sophora extractive and method of preparing the same and application of the same | |
| CN101862357B (en) | Acute turpinia leaf general flavone ethanol reflux extract, and preparation method and application thereof | |
| CN101669979B (en) | Artemisia scoparia extractive and production method and applications thereof | |
| CN102633850A (en) | Rhoifolin extraction method and usage of drug prepared by rhoifolin | |
| CN101884651B (en) | Water extract of turpinia formosana leaves and preparation method and application thereof | |
| CN101897715B (en) | Nuezhenoside and rhoifolin composition and use thereof in preparation of drugs | |
| CN101899078B (en) | Extraction method of glossy privet fruit glycoside and application of glossy privet fruit glycoside in preparation of medicament | |
| CN101904859B (en) | Rhoifolin and hyperin composition and application of medicines prepared therefrom | |
| CN101890037B (en) | Nuezhenoside and hyperin composition and application thereof for preparing medicine | |
| CN102526086A (en) | Method for extracting ligustroflavone and application of ligustroflavone to preparation of medicines | |
| CN102600194A (en) | Extraction method of hyperoside, and purpose thereof in preparing medicines | |
| CN101879197B (en) | Turpinia Montana leaf ethanol reflux extractive, preparation method and application thereof | |
| CN102935098A (en) | Acute turpinia leaf general flavone ethanol reflux extract, and preparation method and application thereof | |
| CN102920751A (en) | Turpinia arguta leaf total flavonoid ethanol reflux extract, preparation method and uses thereof | |
| CN102784178A (en) | Turpinia montana leaf general flavone ethanol reflux extractive, preparation method and application thereof | |
| CN101862358B (en) | Acute turpinia leaf ethanol percolation extract, and preparation method and application thereof | |
| CN101862359A (en) | Acute turpinia leaf general flavone ethanol reflux extract, and preparation method and application thereof | |
| CN102579515B (en) | Folium turpiniae ethanol percolating extract, preparation method and application thereof | |
| CN102772453A (en) | Turpinia formosana Nakai leaf ethanol backflow extract and preparation method and applications thereof | |
| CN102631383A (en) | Turpinia arguta seen leaf ethanol diacolation extract, preparation method thereof and application | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection | |
| CN102631382A (en) | Turpinia arguta seen leaf ethanol diacolation extract, preparation method thereof and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190116 Address after: 342100 Longquan Road, Xinshan Town, Anyuan County, Ganzhou City, Jiangxi Province, No. 139 Co-patentee after: Jiangxi Qingfeng Pharmaceutical Co., Ltd. Patentee after: Shanxiang Pharmaceutical Co., Ltd., Jiangxi Address before: 342100 Longquan Road, Xinshan Town, Anyuan County, Ganzhou City, Jiangxi Province, No. 139 Co-patentee before: Jiangxi Qingfeng Drugs Research Co., Ltd. Patentee before: Shanxiang Pharmaceutical Co., Ltd., Jiangxi |
|
| TR01 | Transfer of patent right |